290,700 Shares in Bioventus Inc. $BVS Acquired by Knights of Columbus Asset Advisors LLC

Key Points

• Knights of Columbus Asset Advisors LLC acquired 290,700 shares of Bioventus Inc., valued at approximately $1,924,000, increasing their ownership to about 0.35% of the company.
• Analysts have set a price target of $12.00 for Bioventus, with a consensus rating of "Moderate Buy" based on evaluations from multiple investment analysts.
• The stock is currently trading at $6.79, with a market capitalization of $561.39 million and significant institutional ownership at 62.94%.

Knights of Columbus Asset Advisors LLC acquired a new stake in Bioventus Inc. (NYSE:BVS - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 290,700 shares of the company's stock, valued at approximately $1,924,000. Knights of Columbus Asset Advisors LLC owned about 0.35% of Bioventus at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in BVS. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Bioventus in the 4th quarter valued at approximately $684,000. California State Teachers Retirement System lifted its stake in Bioventus by 1,138.9% in the 4th quarter. California State Teachers Retirement System now owns 33,697 shares of the company's stock valued at $354,000 after purchasing an additional 30,977 shares during the last quarter. GAMMA Investing LLC lifted its stake in Bioventus by 3,228.7% in the 1st quarter. GAMMA Investing LLC now owns 5,792 shares of the company's stock valued at $53,000 after purchasing an additional 5,618 shares during the last quarter. Harbor Capital Advisors Inc. bought a new position in Bioventus in the 1st quarter valued at approximately $200,000. Finally, Allspring Global Investments Holdings LLC lifted its stake in Bioventus by 54.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 36,829 shares of the company's stock valued at $337,000 after purchasing an additional 12,915 shares during the last quarter. Institutional investors own 62.94% of the company's stock.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald initiated coverage on shares of Bioventus in a research note on Monday, July 7th. They issued an "overweight" rating and a $12.00 price objective for the company. Three investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $13.75.

Bioventus Price Performance

BVS stock opened at $6.79 on Tuesday. The company has a fifty day moving average price of $7.02 and a 200-day moving average price of $7.12. The company has a market capitalization of $561.39 million, a P/E ratio of -11.13 and a beta of 0.81. Bioventus Inc. has a 52-week low of $5.81 and a 52-week high of $14.38. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.

Want to see what other hedge funds are holding BVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioventus Inc. (NYSE:BVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.